The Medicine Maker

Exploring the human side of drug manufacturing & development 💊

[The Medicine Maker @medicine_maker]

💊 The future of small molecule development is changing fast.

Explore expert insights on API stability, nitrosamine testing, oral dosage innovation, and more in our FREE eBook.

Download now: https://t.co/bdHfBul0wr

Sponsored by @Pfizer and Kindeva
#Pharma #DrugDevelopment

[The Medicine Maker @medicine_maker]

💉 GLP-1 demand is soaring. Can manufacturing keep up?

Tommy Schornak of Kindeva explores how manufacturers can increase capacity without compromising quality or squeezing supply for other injectable therapies.

🏭 Read more: https://t.co/KVAJQeL9eM

#GLP1 #PharmaManufacturing

[The Medicine Maker @medicine_maker]

🧬 Can cell and gene therapy manufacturing keep pace with innovation?

At #ASGCT2026, David Radspinner of VintaBio shares his perspective on what it will take to make advanced therapy manufacturing more scalable.

🎥 Watch: https://t.co/CNqCmebofD

#CellAndGeneTherapy

[The Medicine Maker @medicine_maker]

🧬 How can we bring cell and gene therapies to more patients?

At #ASGCT2026, Francesca Vidali of ReiThera and industry leaders explore how manufacturing, reimbursement and treatment delivery need to evolve.

🎥 Watch: https://t.co/bUPdEMF6sJ

#CellAndGeneTherapy #GeneTherapy

[The Medicine Maker @medicine_maker]

🌟 Meet #PowerList2026 honoree Piers Ingram, CEO and Co-founder of Hummingbird Bioscience.

Piers is applying rational drug design to develop precision antibody therapies for challenging oncology targets.

Congratulations, Piers! 🏆

🔗 Read more: https://t.co/Lg9JzIvtLq

[The Medicine Maker @medicine_maker]

🧬 Can iPSC cell therapies make the leap from lab breakthrough to commercial scale?

Stefan Braam explores the manufacturing challenges behind off-the-shelf cell therapies and what needs to change to make them scalable and accessible.

🔗 https://t.co/6Xcsfd2u9w
#CellTherapy

[The Medicine Maker @medicine_maker]

🎯 What can pharma learn from military intelligence?

Former intelligence officer Tony Page explains why pharma needs to spot signals earlier, challenge assumptions and move beyond “plan, execute, react.”

👉 Read the interview: https://t.co/SNueRVlfaq
#Pharma #Biopharma

[The Medicine Maker @medicine_maker]

🔌 Is your lab building up “integration debt”?

As biopharma labs add more automation, AI and digital tools, disconnected systems can create more failure points and more time spent chasing errors.

Mark Fish explores what needs to change.

🔗 https://t.co/GnyNy4QnqE
#Biopharma

[The Medicine Maker @medicine_maker]

🌱 Is biotech funding finally recovering?

Jon Rees sees signs of progress, but says there’s no going back to the “old normal.”

Discover how investor expectations, competition for capital and the rise of Chinese biotech are reshaping the industry.

🔗 https://t.co/6VfmWfVmZS

[The Medicine Maker @medicine_maker]

💻 “Digital is not a ‘good to have,’ it’s a necessity.”

Alexander Seyf discusses why digitalization, automation, and greater collaboration will be critical to scaling cell and gene therapies.

🔗 Read the interview: https://t.co/hGN2y5hs9r

#CellTherapy #Biomanufacturing

[The Medicine Maker @medicine_maker]

🏆 Have you submitted your innovation yet?

The Medicine Maker Innovation Awards 2026 is celebrating the technologies advancing pharmaceutical development and manufacturing.

📅 Nominations close September 27, 2026.

Submit your entry today: https://t.co/662ihktMpf

[The Medicine Maker @medicine_maker]

🤖 Your AI model can reason. But can it trust the science it’s reasoning over?

Andrea Jacobs explores why curated, verifiable data could matter more than model power when applying AI to drug discovery.

🧪 Read more: https://t.co/ocNMpYffbH

#DrugDiscovery

[The Medicine Maker @medicine_maker]

🧬 Commercial readiness starts early in cell and gene therapy development.

Eytan Abraham of Minaris Advanced Therapies discusses how process development, analytics, and tech transfer can shape scalability and commercial success.

🔗 https://t.co/PzmNewflYs

#CellTherapy

[The Medicine Maker @medicine_maker]

🌍 Could 80 to 85% of today’s biotechs disappear within five years?

Ali Pashazadeh explores a biopharma landscape being reshaped by AI, tighter capital, global competition, and the rise of Chinese biotech.

🔗 Read more: https://t.co/xHDorFU3aK

#Biotech #Biopharma #Pharma

[The Medicine Maker @medicine_maker]

💊 A $20 million freezer failure raises an important question...

Does pharma have a supply chain visibility problem?

Adriana Stalteri explores why real-time inventory visibility is becoming critical for modern medicines.

🔗 https://t.co/B5MBpDbMWf

#Pharma #SupplyChain

[The Medicine Maker @medicine_maker]

🤖 Could confidentiality be the biggest barrier to AI-enabled drug development?

Timothy Pas and Laure Descamps explore how AI can support formulation science while navigating data protection and IP challenges.

📖 https://t.co/zEKpIICkJC
#DrugDevelopment

[The Medicine Maker @medicine_maker]

🚀 What's the most exciting innovation you've launched this year?

If it's helping shape the future of pharmaceutical development or manufacturing, we'd love to hear about it.

📅 Submit your entry before September 27, 2026.

🔗 https://t.co/Lct504okcI

#Pharma

[The Medicine Maker @medicine_maker]

🌟 The Medicine Maker Power List 2026

Congratulations to Reuben Dawkins, Co-founder and CEO of Link Biologics, on being named one of this year's Power List honorees.

🔗 https://t.co/Khv8dI7yuF

#PowerList2026 #Biotech

[The Medicine Maker @medicine_maker]

💊 The future of small molecule development is changing fast.

Explore expert insights on API stability, nitrosamine testing, oral dosage innovation, and more in our FREE eBook.

Download now: https://t.co/bdHfBul0wr

Sponsored by @Pfizer and Kindeva
#Pharma #DrugDevelopment

[The Medicine Maker @medicine_maker]

🌟 The Medicine Maker Power List 2026

Congratulations to Renée Aguiar-Lucander, CEO of Hansa Biopharma, on being named one of this year's Power List honorees.

🔗 https://t.co/dS3T9ubX8u

#PowerList2026 #Biotech